- Status -
- Type New application
- Pre-PASC consultation Not yet started
- Pre-MSAC consultation Not yet started
- Outcome Pending
Application details
Reason for application
New MBS item.
Service or technology in this application
The Stockholm3 is a multiparametric blood-based test that uses protein and genetic analysis combined with clinical data and an algorithm to estimate the risk of having clinically significant prostate cancer. This test is intended for men with no previous prostate cancer diagnosis, aged 45-74 years and have an elevated prostate specific antigen (PSA) level, who want to assess the risk of prostate cancer.
Type: Investigative technology
Medical condition this application addresses
Prostate cancer develops when abnormal cells in the prostate gland grow in an uncontrolled way, forming a malignant tumour. Localised prostate cancer is where the cancer cells do not appear to have spread beyond the prostate, alternatively advanced or metastatic prostate cancer is where the cancer has spread outside the prostate. Prostate cancer is estimated to be the most commonly diagnosed cancer for males and for Australia overall, with an estimated 25,500 cases diagnosed in 2023.
Application documents
Application summary
PICO set
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Consultation survey and deadlines
- PASC consultation: TBA – please subscribe to the MSAC bulletin to be notified when this application is scheduled for PASC consideration. The bulletin will also advise the closing date for consultation input.
- MSAC consultation: TBA – please subscribe to the MSAC bulletin to be notified when this application is scheduled for MSAC consideration. The bulletin will also advise the closing date for consultation input.
Meetings to consider this application
- PASC meeting: -
- ESC meeting: -
- MSAC meeting: -